{
    "questions": [
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/36311548",
                "http://www.ncbi.nlm.nih.gov/pubmed/35653495",
                "http://www.ncbi.nlm.nih.gov/pubmed/34629180",
                "http://www.ncbi.nlm.nih.gov/pubmed/34585455",
                "http://www.ncbi.nlm.nih.gov/pubmed/35911352",
                "http://www.ncbi.nlm.nih.gov/pubmed/36002964"
            ],
            "snippets": [
                {
                    "beginSection": "title",
                    "endSection": "title",
                    "text": "Challenges to the Diagnosis of Functional Neurological Disorder: Feigning, Intentionality, and Responsibility.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36311548",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 110
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "he diagnosis of Functional Neurological Disorder (FND) requires differentiation from other neurologic diseases/syndromes, and from the comparatively rare diagnosis of feigning (Malingering and Factitious Disorder)",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36311548",
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 214
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Functional neurological disorder reflects impairments in brain networks leading to distressing motor, sensory and/or cognitive symptoms that demonstrate positive clinical signs on examination incongruent with other conditions. ",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35653495",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 227
                },
                {
                    "beginSection": "title",
                    "endSection": "title",
                    "text": "Functional neurological disorder and somatic symptom disorder in Parkinson's disease.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34629180",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 85
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "The occurrence of Functional Neurological Disorder (FND) and Somatic Symptom Disorder (SSD) in PD was not commonly accepted until recently, despite some evidence that emerged in the pre and early L-Dopa era. ",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34629180",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 208
                },
                {
                    "beginSection": "title",
                    "endSection": "title",
                    "text": "Maladaptive schemas of patients with functional neurological symptom disorder.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34585455",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 78
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "he psychological underpinnings of functional neurological symptom disorders (FNSD) remain poorly understood. ",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34585455",
                    "offsetInBeginSection": 13,
                    "offsetInEndSection": 122
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "disintegration of explicit and implicit information processing in patients with FNSD has previously been suggested; however, this suggestion has so far received little empirical support. Trauma and maladaptive schemas probably reinforce disintegration in FNSD. The present study explored the occurrence of maladaptive schemas and investigated the impact of trauma-related maladaptive schemas in patients with FNSD.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34585455",
                    "offsetInBeginSection": 124,
                    "offsetInEndSection": 538
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Functional neurological symptom disorder (FND) remains a clinical challenge. It is one of the many mimics of cerebrovascular accidents, spinal cord disorders, and lower motor neuron disease. ",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35911352",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 191
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Previous studies with adults suggest that aberrant communication between neural networks underpins functional neurological disorder (FND). ",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36002964",
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 151
                }
            ],
            "id": "6436953757b1c7a315000028",
            "type": "yesno",
            "body": "Is Functional Neurological Disorder (FND) classified as a psychosomatic disorder?"
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/32142172",
                "http://www.ncbi.nlm.nih.gov/pubmed/31511305",
                "http://www.ncbi.nlm.nih.gov/pubmed/36069349"
            ],
            "snippets": [
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "In this review, it is argued that the relationship between the accessibility and activity of an enhancer is insufficiently described by simply considering open versus closed chromatin, or active versus inactive enhancers. Instead, recent studies focusing on the quantitative nature of accessibility signal reveal subtle differences between active enhancers and their different inactive counterparts: the closed silenced state and the accessible primed and repressed states. While the open structure as such is not a specific indicator of enhancer activity, active enhancers display a higher degree of accessibility than the primed and repressed states.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32142172",
                    "offsetInBeginSection": 173,
                    "offsetInEndSection": 825
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "DNA accessibility is thought to be of major importance in regulating gene expression.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31511305",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 85
                },
                {
                    "beginSection": "title",
                    "endSection": "title",
                    "text": "Accessibility of promoter DNA is not the primary determinant of chromatin-mediated gene regulation.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31511305",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 99
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Euchromatin and heterochromatin have very similar accessibilities, suggesting that transcription factors can penetrate heterochromatin. Thus, DNA accessibility is not likely to be the primary determinant of gene regulation.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31511305",
                    "offsetInBeginSection": 797,
                    "offsetInEndSection": 1020
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "A major goal in the field of transcriptional regulation is the mapping of changes in the binding of transcription factors to the resultant changes in gene expression.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36069349",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 166
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Together, these results show many gene expression changes can happen independently of changes in the accessibility of local chromatin in the context of a single-factor perturbation.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36069349",
                    "offsetInBeginSection": 1692,
                    "offsetInEndSection": 1873
                }
            ],
            "id": "645004fa57b1c7a31500008b",
            "type": "yesno",
            "body": "Are accessible enhancers necessarily active?"
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/35921451"
            ],
            "snippets": [
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "CONCLUSIONS: Prasinezumab therapy had no meaningful effect on global or imaging measures of Parkinson's disease progression as compared with placebo and was associated with infusion reactions. ",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35921451",
                    "offsetInBeginSection": 2015,
                    "offsetInEndSection": 2208
                }
            ],
            "id": "63eef9b6f36125a426000011",
            "type": "yesno",
            "body": "Is Prasinezumab effective for Parkinson\u2019s Disease?"
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/35857660"
            ],
            "snippets": [
                {
                    "beginSection": "title",
                    "endSection": "title",
                    "text": "Phase 1-2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35857660",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 68
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "BACKGROUND: FLT180a (verbrinacogene setparvovec) is a liver-directed adeno-associated virus (AAV) gene therapy that uses a synthetic capsid and a gain-of-function protein to normalize factor IX levels in patients with hemophilia B",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35857660",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 230
                }
            ],
            "id": "63f02e1bf36125a426000016",
            "type": "yesno",
            "body": "Was AAVS3 developed for hemophilia A?"
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/35381889",
                "http://www.ncbi.nlm.nih.gov/pubmed/34460113",
                "http://www.ncbi.nlm.nih.gov/pubmed/32868463",
                "http://www.ncbi.nlm.nih.gov/pubmed/31162719"
            ],
            "snippets": [
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Developmental iron deficiency (dID) models facilitate the study of specific oligodendrocyte (OL) requirements for their progression to a mature state and subsequent contribution to myelinatio",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31162719",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 191
                },
                {
                    "beginSection": "title",
                    "endSection": "title",
                    "text": "Ontogenetic oligodendrocyte maturation through gestational iron deprivation: The road not taken.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31162719",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 96
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": " the expression levels of Hes5, Sox10, and Olig1 in dID conditions correlated with an unfavorable OL maturation profile.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31162719",
                    "offsetInBeginSection": 1444,
                    "offsetInEndSection": 1564
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": " the current results provide further evidence of dID impact on myelination, keeping OL away from the maturational path.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31162719",
                    "offsetInBeginSection": 1572,
                    "offsetInEndSection": 1691
                },
                {
                    "beginSection": "title",
                    "endSection": "title",
                    "text": "Impaired Postnatal Myelination in a Conditional Knockout Mouse for the Ferritin Heavy Chain in Oligodendroglial Cells.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32868463",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 118
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "To define the importance of iron storage in oligodendrocyte development and function, the ferritin heavy subunit (Fth) was specifically deleted in oligodendroglial cells.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32868463",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 170
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Fth iron storage is essential for early oligodendrocyte development as well as for OPC maturation in the demyelinated adult brain.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32868463",
                    "offsetInBeginSection": 2314,
                    "offsetInEndSection": 2444
                },
                {
                    "beginSection": "title",
                    "endSection": "title",
                    "text": "H-ferritin expression in astrocytes is necessary for proper oligodendrocyte development and myelination.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34460113",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 104
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": " These results indicate that Fth iron storage in astrocytes is vital for early oligodendrocyte development as well as for the remyelination of the CNS.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34460113",
                    "offsetInBeginSection": 1478,
                    "offsetInEndSection": 1629
                }
            ],
            "id": "6419d79c690f196b5100003b",
            "type": "yesno",
            "body": "Does iron regulate oligodendrocyte maturation?"
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21734376",
                "http://www.ncbi.nlm.nih.gov/pubmed/26216216"
            ],
            "snippets": [
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Epigenetics is defined as heritable changes in gene expression that are, unlike mutations, not attributable to alterations in the sequence of DNA. The predominant epigenetic mechanisms are DNA methylation, modifications to chromatin, loss of imprinting and non-coding RNA.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21734376",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 272
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Genome-wide association studies of complex physiological traits and diseases consistently found that associated genetic factors, such as allelic polymorphisms or DNA mutations, only explained a minority of the expected heritable fraction. This discrepancy is known as \"missing heritability\", and its underlying factors and molecular mechanisms are not established. Epigenetic programs may account for a significant fraction of the \"missing heritability.\" Epigenetic modifications, such as DNA methylation and chromatin assembly states, reflect the high plasticity of the genome and contribute to stably alter gene expression without modifying genomic DNA sequences.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26216216",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 665
                }
            ],
            "id": "644efd5157b1c7a315000086",
            "type": "yesno",
            "body": "Are epigenetic changes heritable?"
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26216216",
                "http://www.ncbi.nlm.nih.gov/pubmed/21734376",
                "http://www.ncbi.nlm.nih.gov/pubmed/33781317"
            ],
            "snippets": [
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Epigenetic modifications, such as DNA methylation and chromatin assembly states, reflect the high plasticity of the genome and contribute to stably alter gene expression without modifying genomic DNA sequences.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26216216",
                    "offsetInBeginSection": 455,
                    "offsetInEndSection": 665
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Epigenetics is defined as heritable changes in gene expression that are, unlike mutations, not attributable to alterations in the sequence of DNA.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21734376",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 146
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Epigenetic changes are inheritable modifications that can modify the gene expression without changing the DNA sequence. The most common epigenetic alternations consist of DNA methylation and histone modifications.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33781317",
                    "offsetInBeginSection": 125,
                    "offsetInEndSection": 338
                }
            ],
            "id": "644efd2c57b1c7a315000085",
            "type": "yesno",
            "body": "Do epigenetic changes change the DNA sequence?"
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29298167"
            ],
            "snippets": [
                {
                    "beginSection": "title",
                    "endSection": "title",
                    "text": "Newly Developed Skin Picking After Methylphenidate Treatment in Attention Deficit Hyperactivity Disorder: Possible Mechanisms.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29298167",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 126
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "We describe a case of skin picking developing after methylphenidate therapy for ADHD.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29298167",
                    "offsetInBeginSection": 820,
                    "offsetInEndSection": 905
                }
            ],
            "id": "6414c5ba690f196b51000007",
            "type": "yesno",
            "body": "Can skin picking phenotype present following methylphenidate treatment?"
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/31993419"
            ],
            "snippets": [
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Enhancers are cis-regulatory elements in the genome that cooperate with promoters to control target gene transcription. Unlike promoters, enhancers are not necessarily adjacent to target genes and can exert their functions regardless of enhancer orientations, positions and spatial segregations from target genes.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31993419",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 313
                }
            ],
            "id": "644f0fd257b1c7a31500008a",
            "type": "yesno",
            "body": "Do enhancers have to be close to their gene targets?"
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/34794294",
                "http://www.ncbi.nlm.nih.gov/pubmed/8283989",
                "http://www.ncbi.nlm.nih.gov/pubmed/2801018"
            ],
            "snippets": [
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Spinal muscular atrophy (SMA) with respiratory distress type 1 (SMARD1) is an exceptionally rare type of SMA.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34794294",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 109
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "There are no convincing reports of X-linked SMA hitherto. ",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8283989",
                    "offsetInBeginSection": 902,
                    "offsetInEndSection": 960
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "The total AChE activity was either normal or decreased in the childhood SMA (Type 1), the other SMA groups and disease controls (ALS, X-linked SMA).",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2801018",
                    "offsetInBeginSection": 146,
                    "offsetInEndSection": 294
                }
            ],
            "id": "64463f9357b1c7a31500006a",
            "type": "yesno",
            "body": "Are there any other types of Spinal Muscular Atrophy except for types 1-4?"
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/33609476"
            ],
            "snippets": [
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "INTERPRETATION: A similar safety profile was seen in all treatment groups. No beneficial treatment effects were recorded. Although this study did not provide evidence of efficacy in progressive supranuclear palsy, the findings provide potentially useful information for future investigations of passive immunisation using tau antibodies for progressive supranuclear palsy.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33609476",
                    "offsetInBeginSection": 2991,
                    "offsetInEndSection": 3363
                }
            ],
            "id": "640418af201352f04a000018",
            "type": "yesno",
            "body": "Is Tilavonemab effective for progressive supranuclear palsy?"
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/35042956",
                "http://www.ncbi.nlm.nih.gov/pubmed/33394459"
            ],
            "snippets": [
                {
                    "beginSection": "title",
                    "endSection": "title",
                    "text": "No infectious SARS-CoV-2 in breast milk from a cohort of 110 lactating women.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35042956",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 77
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "SARS-CoV-2 RNA can be found infrequently in the breastmilk after recent infection, but we found no evidence that breastmilk contains an infectious virus or that breastfeeding represents a risk factor for transmission of infection to infants.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35042956",
                    "offsetInBeginSection": 1169,
                    "offsetInEndSection": 1410
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "This article goes beyond prior small studies to provide evidence that infectious SARS-CoV-2 is not present in the milk of lactating women with recent infection, even when SARS-CoV-2 RNA is detected.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35042956",
                    "offsetInBeginSection": 1418,
                    "offsetInEndSection": 1616
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Recent SARS-CoV-2 infection or detection of its RNA in human milk is not a contraindication to breastfeeding.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35042956",
                    "offsetInBeginSection": 1617,
                    "offsetInEndSection": 1726
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Based on the currently available limited evidence and recognizing the benefits of breastfeeding, it may be concluded that if the health of the mother and her newborn allows, direct breastfeeding or extracted breastmilk should be encouraged by the healthcare providers after a careful discussion of the risks of vertical transmission to the mother and her family",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33394459",
                    "offsetInBeginSection": 1065,
                    "offsetInEndSection": 1426
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Preventive measures should be taken by COVID-19 mothers to prevent droplet transmission of infection to the infants while breastfeeding.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33394459",
                    "offsetInBeginSection": 1428,
                    "offsetInEndSection": 1564
                }
            ],
            "id": "641791ed690f196b51000032",
            "type": "yesno",
            "body": "Is SARS-CoV-2 transmitted through breast milk?"
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/31794465",
                "http://www.ncbi.nlm.nih.gov/pubmed/35428982"
            ],
            "snippets": [
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "The treatment of FSHD is currently supportive only.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31794465",
                    "offsetInBeginSection": 1218,
                    "offsetInEndSection": 1269
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Facioscapulohumeral muscular dystrophy (FSHD) is a slowly progressive muscular dystrophy without approved therapies.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35428982",
                    "offsetInBeginSection": 19,
                    "offsetInEndSection": 135
                }
            ],
            "id": "644284a957b1c7a31500005c",
            "type": "yesno",
            "body": "Is there any treatment for the Facioscapulohumeral Muscular Dystrophy?"
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/12867081",
                "http://www.ncbi.nlm.nih.gov/pubmed/21266472",
                "http://www.ncbi.nlm.nih.gov/pubmed/15215523",
                "http://www.ncbi.nlm.nih.gov/pubmed/28369664",
                "http://www.ncbi.nlm.nih.gov/pubmed/28334756",
                "http://www.ncbi.nlm.nih.gov/pubmed/9710598"
            ],
            "snippets": [
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "The use of several translation initiation codons in a single mRNA, by expressing several proteins from a single gene, contributes to the generation of protein diversity. A small, yet growing, number of mammalian mRNAs initiate translation from a non-AUG codon, in addition to initiating at a downstream in-frame AUG codon. Translation initiation on such mRNAs results in the synthesis of proteins harbouring different amino terminal domains potentially conferring on these isoforms distinct functions.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12867081",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 501
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "In eukaryotes, it is generally assumed that translation initiation occurs at the AUG codon closest to the messenger RNA 5' cap. However, in certain cases, initiation can occur at codons differing from AUG by a single nucleotide, especially the codons CUG, UUG, GUG, ACG, AUA and AUU. While non-AUG initiation has been experimentally verified for a handful of human genes, the full extent to which this phenomenon is utilized--both for increased coding capacity and potentially also for novel regulatory mechanisms--remains unclear.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21266472",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 531
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "The removal of N-terminal translation initiator Met by methionine aminopeptidase (MetAP) is often crucial for the function and stability of proteins.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15215523",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 149
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Protein synthesis is initiated by methionine in eukaryotes and by formylmethionine in prokaryotes. N-terminal methionine can be co-translationally cleaved by the enzyme methionine aminopeptidase (MAP).",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28369664",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 201
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Our understanding of translation underpins our capacity to engineer living systems. The canonical start codon (AUG) and a few near-cognates (GUG, UUG) are considered as the 'start codons' for translation initiation in Escherichia coli.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28334756",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 235
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Translation from non-canonical start codons ranged from 0.007 to 3% relative to translation from AUG.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28334756",
                    "offsetInBeginSection": 571,
                    "offsetInEndSection": 672
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Protein synthesis is initiated universally with the amino acid methionine. In Escherichia coli, studies with anticodon sequence mutants of the initiator methionine tRNA have shown that protein synthesis can be initiated with several other amino acids. In eukaryotic systems, however, a yeast initiator tRNA aminoacylated with isoleucine was found to be inactive in initiation in mammalian cell extracts.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9710598",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 403
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Our results show that in the presence of the corresponding mutant initiator tRNAs, AGG and GUC can initiate protein synthesis in COS1 cells with methionine and valine, respectively. CAG initiates protein synthesis with glutamine but extremely poorly, whereas UAG could not be used to initiate protein synthesis with glutamine.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9710598",
                    "offsetInBeginSection": 881,
                    "offsetInEndSection": 1207
                }
            ],
            "id": "644e642a57b1c7a315000075",
            "type": "yesno",
            "body": "Do all proteins start with methionine?"
        }
    ]
}